Four-year effectiveness, safety and drug retention rate of secukinumab in psoriatic arthritis: a real-life Italian multicenter cohort.
Biologics
Drug retention rate
Psoriatic arthritis
Remission/Effectiveness
Safety
Secukinumab
Journal
Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438
Informations de publication
Date de publication:
28 Sep 2024
28 Sep 2024
Historique:
received:
16
03
2024
accepted:
15
09
2024
medline:
29
9
2024
pubmed:
29
9
2024
entrez:
28
9
2024
Statut:
epublish
Résumé
to evaluate over a 48-month follow-up period the: 1) long-term effectiveness and safety; 2) drug retention rate (DRR); 3) impact of comorbidities and bDMARDs line on MDA and DAPSA remission/low disease activity (LDA) of secukinumab in a multicenter Italian cohort of PsA patients. Consecutive PsA patients receiving secukinumab were followed prospectively in Italian centers between 2016 and 2023. Disease characteristics, previous/ongoing treatments, comorbidities and follow-up duration were recorded. Treatment response was evaluated at 6 and 12 months after initiation, and every year up to 48 months (T48). DRR was assessed according to clinical and demographic features, comorbidities and bDMARDs line. Adverse events (AE) were recorded. Six hundred eighty-five patients [42.5% male] were enrolled; 32.9% naïve received secukinumab; 74.2% had ≥ 1 comorbidity. Overall, secukinumab yielded improved outcomes at T48: naïve maintained lower disease activity vs. non-naïve [DAPSA 4.0 (1.4-8.1) vs. 6.0 (2.2-10.4);p = 0.04]; 76.9% naïve and 66.2% non-naïve achieved MDA; MDA no comorbidities vs. 1-3 comorbidities 78.8% vs. 73.3% (p < 0.05), and MDA no comorbidities vs. > 3 comorbidities 78.8% vs. 48.7% (p < 0.001). DAPSA-REM and DAPSA-LDA rates were higher in naïve patients, albeit similar between those without comorbidities vs. 1-3 comorbidities, and slightly lower in those with > 3 comorbidities. Treatment was discontinued in 233 patients due to loss of effectiveness, and in 41 due to AE. The overall DRR at T48 was 66%, with differences according to bDMARDs line (p < 0.001), use of combined csDMARDs (p = 0.016), BMI (p = 0.037) and mono/oligoarthritis vs. polyarthritis (p = 0.012). Secukinumab proved safe and effective, and patients achieved sustained remission with a notable drug retention rate at 4 years.
Identifiants
pubmed: 39342310
doi: 10.1186/s13075-024-03401-x
pii: 10.1186/s13075-024-03401-x
doi:
Substances chimiques
secukinumab
DLG4EML025
Antibodies, Monoclonal, Humanized
0
Antirheumatic Agents
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
172Investigateurs
Roberta Foti
(R)
Elisa Visalli
(E)
Ylenia Dal Bosco
(Y)
De Lucia Francesco
(L)
Cesaro Siracusano
(C)
Sergio Collela
(S)
Nicoletta Luciano
(N)
Valentino Paci
(V)
Giulia Marchionni
(G)
Nicolò Girolimetto
(N)
Alberto Floris
(A)
Giorgia Citriniti
(G)
Giovanni Striani
(G)
Antonio Carriero
(A)
Roberta Foti
(R)
Elisa Visalli
(E)
Ylenia Dal Bosco
(Y)
De Lucia Francesco
(L)
Cesaro Siracusano
(C)
Sergio Collela
(S)
Giacomo M Guidelli
(GM)
Nicoletta Luciano
(N)
Valentino Paci
(V)
Giulia Marchionni
(G)
Nicolò Girolimetto
(N)
Alberto Floris
(A)
Giorgia Citriniti
(G)
Giovanni Striani
(G)
Informations de copyright
© 2024. The Author(s).
Références
Gladman D, Antoni C, Mease P, Clegg D, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64(Suppl 2):ii14–7. https://doi.org/10.1136/ard.2004.032482 .
doi: 10.1136/ard.2004.032482
pubmed: 15708927
pmcid: 1766874
Gladman D. Early psoriatic arthritis. Rheum Dis Clin North Am. 2012;38(2):373–86. https://doi.org/10.1016/j.rdc.2012.05.005 .
doi: 10.1016/j.rdc.2012.05.005
pubmed: 22819090
Mease PJ, Armstrong AW. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs. 2014;74:423–41. https://doi.org/10.1007/s40265-014-0191-y .
doi: 10.1007/s40265-014-0191-y
pubmed: 24566842
pmcid: 3958815
Denis A, Sztejkowski C, Arnaud L, Becker G, Felten R. The 2023 pipeline of disease-modifying antirheumatic drugs (DMARDs) in clinical development for spondyloarthritis (including psoriatic arthritis): a systematic review of trials. RMD Open. 2023;9(3): e003279. https://doi.org/10.1136/rmdopen-2023-003279 .
doi: 10.1136/rmdopen-2023-003279
pubmed: 37507210
pmcid: 10387652
Colombo D, Frassi M, Pagano Mariano G, the CHRONOS Study Group. Real-world evidence of biologic treatments in psoriatic arthritis in Italy: results of the CHRONOS (EffeCtiveness of biologic treatments for psoriatic artHRitis in Italy: an ObservatioNal lOngitudinal Study of real-life clinical practice) observational longitudinal study. BMC Rheumatol. 2022;6(1):57. https://doi.org/10.1186/s41927-022-00284-w .
doi: 10.1186/s41927-022-00284-w
pubmed: 36089612
pmcid: 9464489
Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700–12. https://doi.org/10.1136/annrheumdis-2020-217159 .
doi: 10.1136/annrheumdis-2020-217159
pubmed: 32434812
Coates LC, Soriano ER, Corp N, et al. GRAPPA Treatment recommendations domain subcommittees Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465–79. https://doi.org/10.1038/s41584-022-00798-0 .
doi: 10.1038/s41584-022-00798-0
pubmed: 35761070
pmcid: 9244095
Marchesoni A, Olivieri I, Salvarani C, et al. Recommendations for the use of biologics and other novel drugs in the treatment of psoriatic arthritis: 2017 update from the Italian society of Rheumatology. Clin Exp Rheumatol. 2017;35(6):991–1010.
pubmed: 29185959
Langley RG, Elewski BE, Lebwohl M, ERASURE Study Group; FIXTURE Study Group, et al. Secukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med. 2014;371(4):326–38. https://doi.org/10.1056/NEJMoa1314258 .
doi: 10.1056/NEJMoa1314258
pubmed: 25007392
McInnes IB, Mease PJ, Kirkham B, et al. FUTURE 2 Study Group. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(9999):1137–46. https://doi.org/10.1016/S0140-6736(15)61134-5 .
doi: 10.1016/S0140-6736(15)61134-5
pubmed: 26135703
Baeten D, Sieper J, Braun J, MEASURE 1 Study Group; MEASURE 2 Study Group, et al. Secukinumab, an Interleukin-17A inhibitor, in Ankylosing Spondylitis. N Engl J Med. 2015;373(26):2534–48. https://doi.org/10.1056/NEJMoa1505066 .
doi: 10.1056/NEJMoa1505066
pubmed: 26699169
Mease PJ, Kavanaugh A, Reimold A, et al. FUTURE 1 study group. Secukinumab provides sustained improvements in the signs and symptoms of psoriatic arthritis: final 5-year results from the phase 3 FUTURE 1 study. ACR Open Rheumatol. 2020;2(1):18–25. https://doi.org/10.1002/acr2.11097 .
doi: 10.1002/acr2.11097
pubmed: 31943974
McInnes IB, Behrens F, Mease PJ, EXCEED Study Group, et al. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel- group, randomised, active-controlled, phase 3b trial. Lancet. 2020;395(10235):1496–505. https://doi.org/10.1016/S0140-6736(20)30564-X .
doi: 10.1016/S0140-6736(20)30564-X
pubmed: 32386593
Coates LC, Mease PJ, Gladman DD, Navarra S, Bao W, Gaillez C. Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study. RMD Open. 2023;9(2):e002939. https://doi.org/10.1136/rmdopen-2022-002939 .
doi: 10.1136/rmdopen-2022-002939
pubmed: 37094983
pmcid: 10124319
Deodhar A, Mease PJ, McInnes IB, et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther. 2019;21(1):111. https://doi.org/10.1186/s13075-019-1882-2 .
doi: 10.1186/s13075-019-1882-2
pubmed: 31046809
pmcid: 6498580
Mease P, van der Heijde D, Landewé R, et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Ann Rheum Dis. 2018;77(6):890–7. https://doi.org/10.1136/annrheumdis-2017-212687 .
doi: 10.1136/annrheumdis-2017-212687
pubmed: 29550766
Nash P, Mease PJ, McInnes IB, et al. FUTURE 3 study group. Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3). Arthritis Res Ther. 2018;20(1):47. https://doi.org/10.1186/s13075-018-1551-x .
doi: 10.1186/s13075-018-1551-x
pubmed: 29544534
pmcid: 5856314
Shirley M, Scott LJ. Secukinumab: a review in psoriatic arthritis. Drugs. 2016;76:1135–45. https://doi.org/10.1007/s40265-016-0602-3 .
doi: 10.1007/s40265-016-0602-3
pubmed: 27299434
Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS. Interpretation and impact of real-world Clinical Data for the practicing clinician. Adv Ther. 2018;35(11):1763–74. https://doi.org/10.1007/s12325-018-0805-y .
doi: 10.1007/s12325-018-0805-y
pubmed: 30357570
pmcid: 6223979
Fortin M, Dionne J, Pinho G, Gignac J, Almirall J, Lapointe L. Randomized controlled trials: do they have external validity for patients with multiple comorbidities? Ann Fam Med. 2006;4(2):104–8. https://doi.org/10.1370/afm.516 .
doi: 10.1370/afm.516
pubmed: 16569712
pmcid: 1467012
Chimenti MS, Fonti GL, Conigliaro P, et al. One-year effectiveness, retention rate, and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicenter study. Expert Opin Biol Ther. 2020;20(7):813–21. https://doi.org/10.1080/14712598.2020.1761957 .
doi: 10.1080/14712598.2020.1761957
pubmed: 32401062
Ramonda R, Lorenzin M, Sole Chimenti M, et al. Effectiveness and safety of secukinumab in axial spondyloarthritis: a 24-month prospective, multicenter real-life study. Ther Adv Musculoskelet Dis. 2022;14:1759720X221090310. https://doi.org/10.1177/1759720X221090310 .
doi: 10.1177/1759720X221090310
pubmed: 35510168
pmcid: 9058366
Dastoli S, Passante M, Loconsole F, et al. Long-term efficacy and safety of secukinumab in real life: a 240 weeks multicenter study from Southern Italy. J Dermatolog Treat. 2023;34(1):2200868. https://doi.org/10.1080/09546634.2023.2200868 .
doi: 10.1080/09546634.2023.2200868
pubmed: 37026590
Kiltz U, Sfikakis PP, Gaffney K, et al. Secukinumab Use in patients with moderate to severe psoriasis, Psoriatic Arthritis and Ankylosing spondylitis in Real-World setting in Europe: Baseline Data from SERENA Study. Adv Ther. 2020;37(6):2865–83. https://doi.org/10.1007/s12325-020-01352-8 .
doi: 10.1007/s12325-020-01352-8
pubmed: 32378070
pmcid: 7467439
Michelsen B, Georgiadis S, Di Giuseppe D, et al. Real-world six- and twelve-Month Drug Retention, Remission, and response rates of Secukinumab in 2,017 patients with psoriatic arthritis in Thirteen European Countries. Arthritis Care Res (Hoboken). 2022;74(7):1205–18. https://doi.org/10.1002/acr.24560 .
doi: 10.1002/acr.24560
pubmed: 33460531
Valero-Expósito M, Martín-López M, Guillén-Astete C, et al. Retention rate of secukinumab in psoriatic arthritis: real-world data results from a Spanish multicenter cohort. Med (Baltim). 2022;101(36):e30444. https://doi.org/10.1097/MD.0000000000030444 .
doi: 10.1097/MD.0000000000030444
Glintborg B, Ostergaard M, Krogh NS, et al. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry. Arthritis Rheum. 2013;65(5):1213–23. https://doi.org/10.1002/art.37876 .
doi: 10.1002/art.37876
pubmed: 23460467
Lorenzin M, Ortolan A, Cozzi G, et al. Predictive factors for switching in patients with psoriatic arthritis undergoing anti-TNFα, anti-IL12/23, or anti-IL17 drugs: a 15-year monocentric real-life study. Clin Rheumatol. 2021;40(11):4569–80. https://doi.org/10.1007/s10067-021-05799-0 .
doi: 10.1007/s10067-021-05799-0
pubmed: 34136971
pmcid: 8519923
Cañete JD, Tasende JAP, Laserna FJR, Castro SG, Queiro R. The impact of comorbidity on patient-reported outcomes in psoriatic arthritis: a systematic literature review. Rheumatol Ther. 2020;7:237–57. https://doi.org/10.1007/s40744-020-00202-x .
doi: 10.1007/s40744-020-00202-x
pubmed: 32270447
pmcid: 7211228
Scagnellato L, Collesei A, Doria A, GISEA Study Group, et al. Comorbidities in the Spondyloarthritis GISEA cohort: an average treatment effect analysis on patients treated with bDMARDs. Clin Exp Rheumatol. 2023;30. https://doi.org/10.55563/clinexprheumatol/q38lu0 .
Ruscitti P, Pantano I, Perrotta FM, et al. The assessment of the drug retention rate of secukinumab in patients with psoriatic arthritis in a real-life multicentre cohort. Clin Exp Rheumatol. 2023;24. https://doi.org/10.55563/clinexprheumatol/tpp63h .
García-Dorta A, León-Suarez P, Peña S, et al. Association of Gender, diagnosis, and obesity with Retention Rate of Secukinumab in Spondyloarthropathies: results form a Multicenter Real-World Study. Front Med (Lausanne). 2022;8: 815881. https://doi.org/10.3389/fmed.2021.815881 .
doi: 10.3389/fmed.2021.815881
pubmed: 35096907
Alonso S, Villa I, Fernández S, et al. Multicenter Study of Secukinumab Survival and Safety in Spondyloarthritis and Psoriatic Arthritis: SEcukinumab in Cantabria and ASTURias Study. Front Med (Lausanne). 2021;8: 679009. https://doi.org/10.3389/fmed.2021.679009 .
doi: 10.3389/fmed.2021.679009
pubmed: 34124110
Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665–73. https://doi.org/10.1002/art.21972 .
doi: 10.1002/art.21972
pubmed: 16871531
Secukinumab. Summary of product characteristics. Available from: http://www.ema.europa.eu/index.jsp?curl=pages/medicines/human/medicines/003729/human_med_001832.jsp&mid=WC0b01ac058001d124cited . Cited 2019. Apr 25.
Mease PJ. Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res (Hoboken). 2011;63 Suppl 11:S64-85. https://doi.org/10.1002/acr.20577 .
doi: 10.1002/acr.20577
pubmed: 22588772
Coates LC, Helliwell PS. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res (Hoboken). 2010;62(7):965–9. https://doi.org/10.1002/acr.20155 .
doi: 10.1002/acr.20155
pubmed: 20589696
Schoels MM, Aletaha D, Alasti F, Smolen JS. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis. 2016;75(5):811–8. https://doi.org/10.1136/annrheumdis-2015-207507 .
doi: 10.1136/annrheumdis-2015-207507
pubmed: 26269398
Glintborg B, Di Giuseppe D, Wallman JK, et al. Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: results from five nordic biologics registries. Ann Rheum Dis. 2023;82(6):820–8. https://doi.org/10.1136/ard-2022-223650 .
doi: 10.1136/ard-2022-223650
pubmed: 36813538
Fagerli KM, Lie E, van der Heijde D, et al. Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study. Ann Rheum Dis. 2013;72:1840–4. https://doi.org/10.1136/annrheumdis-2012-203018 .
doi: 10.1136/annrheumdis-2012-203018
pubmed: 23562987
Orbai A-M, McInnes IB, Coates LC, et al. Effect of Secukinumab on the different GRAPPA-OMERACT core domains in psoriatic arthritis: a pooled analysis of 2049 patients. J Rheumatol. 2020;47:854–64. https://doi.org/10.3899/jrheum.190507 .
doi: 10.3899/jrheum.190507
pubmed: 31615919
Coates LC, Gladman DD, Nash P, et al. FUTURE 2 study group. Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study. Arthritis Res Ther. 2018;20(1):272. https://doi.org/10.1186/s13075-018-1773-y .
doi: 10.1186/s13075-018-1773-y
pubmed: 30526678
pmcid: 6286532
Moreno-Ramos MJ, Sanchez-Piedra C, Martínez-González O, et al. Real-world effectiveness and Treatment Retention of Secukinumab in patients with psoriatic arthritis and Axial spondyloarthritis: a descriptive observational analysis of the Spanish BIOBADASER Registry. Rheumatol Ther. 2022;9(4):1031–47. https://doi.org/10.1007/s40744-022-00446-9 .
doi: 10.1007/s40744-022-00446-9
pubmed: 35467242
pmcid: 9314517
Ramonda R, Puato M, Punzi L, et al. Atherosclerosis progression in psoriatic arthritis patients despite the treatment with tumor necrosis factor-alpha blockers: a two-year prospective observational study. Joint Bone Spine. 2014;81(5):421–5. https://doi.org/10.1016/j.jbspin.2014.02.005 .
doi: 10.1016/j.jbspin.2014.02.005
pubmed: 24703399
Kim JH, Choi IA. Cardiovascular morbidity and mortality in patients with spondyloarthritis: a me-ta-analysis. Int J Rheum Dis. 2021;24(4):477–86. https://doi.org/10.1111/1756-185X.13970 .
doi: 10.1111/1756-185X.13970
pubmed: 32969177
Ortolan A, Lorenzin M, Felicetti M, Ramonda R. Do obesity and overweight influence Disease Activity measures in Axial Spondyloarthritis? A systematic review and Meta-analysis. Arthritis Care Res. 2021;73(12):1815–25. https://doi.org/10.1002/acr.24416 .
doi: 10.1002/acr.24416
Pantano I, Iacono D, Favalli EG, et al. Secukinumab efficacy in patients with PsA is not dependent on patients’ body mass index. Ann Rheum Dis. 2022;81(3):e42. https://doi.org/10.1136/annrheumdis-2020-217251 .
doi: 10.1136/annrheumdis-2020-217251
pubmed: 32169970
von Stebut E, Boehncke WH, Ghoreschi K, et al. IL-17A in Psoriasis and Beyond: Cardiovascular and metabolic implications. Front Immunol. 2020;10: 3096. https://doi.org/10.3389/fimmu.2019.03096 .
doi: 10.3389/fimmu.2019.03096
Ortolan A, Lorenzin M, Leo G, et al. Secukinumab Drug Survival in Psoriasis and Psoriatic Arthritis patients: a 24-Month Real-Life Study. Dermatology. 2022;238(5):897–903. https://doi.org/10.1159/000522008 .
doi: 10.1159/000522008
pubmed: 35263743
Baraliakos X, Gossec L, Pournara E, et al. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. Ann Rheum Dis. 2021;80(5):582–90. https://doi.org/10.1136/annrheumdis-2020-218808 .
doi: 10.1136/annrheumdis-2020-218808
pubmed: 33334727
Adami G, Idolazzi L, Benini C, et al. Secukinumab retention rate is greater in patients with psoriatic arthritis presenting with axial involvement. Reumatismo. 2023;75(1). https://doi.org/10.4081/reumatismo.2023.1559 .
Fassio A, Atzeni F, Rossini M, On Behalf Of The Study Group On Osteoporosis And Skeletal Metabolic Diseases Of The Italian Society Of Rheumatology, et al. Osteoimmunology of Spondyloarthritis. Int J Mol Sci. 2023;24(19): 14924. https://doi.org/10.3390/ijms241914924 .
doi: 10.3390/ijms241914924
pubmed: 37834372
pmcid: 10573470
Fassio A, Gatti D, Rossini M, et al. Secukinumab produces a quick increase in WNT signalling antagonists in patients with psoriatic arthritis. Clin Exp Rheumatol. 2019;37(1):133–6.
pubmed: 30418122
Braun J, Buehring B, Baraliakos X, et al. Effects of Secukinumab on Bone Mineral density and bone turnover biomarkers in patients with Ankylosing spondylitis: 2-Year Data from a phase 3 study, MEASURE 1. BMC Musculoskelet Disord. 2021;22:1037. https://doi.org/10.1186/s12891-021-04930-1 .
doi: 10.1186/s12891-021-04930-1
pubmed: 34903218
pmcid: 8670267
Schreiber S, Colombel J-F, Feagan BG, et al. Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials. Ann Rheum Dis. 2019;78:473–9. https://doi.org/10.1136/annrheumdis-2018-214273 .
doi: 10.1136/annrheumdis-2018-214273
pubmed: 30674475